Inflammatory Response With Different Lipid Emulsions In Parenteral Nutrition In Children After Bone Marrow Transplantation
NCT02199821 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14
Last updated 2014-07-25
Summary
Background and Aims: Nutritional support is considered an integral part of the supportive care of bone marrow transplantation patients. Parenteral nutrition emulsions enriched with omega-3 fatty acids can modify the inflammatory response. The aim of this study is to compare plasma cytokines levels in children after bone marrow transplantation using a lipid formula enriched in n-3 FA and other classic soybean oil formula in parenteral nutrition.
Methods: A randomized double blinded controlled study including 14 children with BMT and requiring PN for at least 10 days was conducted using a lipid emulsion with fish oil, or soybean oil. Blood samples at baseline, at 10 days and at the end of the PN were taken to analyze plasma interleukins 1 beta, 2, 6, 8, 10 (IL-10) and tumor necrosis factor alpha (TNF-α).
Conditions
- Bone Narrow Transplantation
Interventions
- DIETARY_SUPPLEMENT
-
Formula with soybean oil, medium-chain triglycerides
- DIETARY_SUPPLEMENT
-
Soybean oil formula commonly used in the hospital
Sponsors & Collaborators
-
Maimónides Biomedical Research Institute of Córdoba
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 1 Day
- Max Age
- 14 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-02-28
- Primary Completion
- 2013-02-28
- Completion
- 2014-02-28
More Related Trials
-
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia
NCT00167167 ·Status: COMPLETED ·Phase: NA
-
Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
NCT00841724 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML
NCT00887042 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
NCT01772953 ·Status: COMPLETED ·Phase: PHASE2
-
Effects on Glutamine on the Outcome of Allogeneic Bone Marrow Transplant Recipients
NCT00563498 ·Status: UNKNOWN ·Phase: NA
-
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
NCT06564493 ·Status: RECRUITING ·Phase: PHASE2
-
Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies
NCT01247701 ·Status: COMPLETED ·Phase: NA
-
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
NCT04965597 ·Status: COMPLETED ·Phase: PHASE2
-
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
NCT01962636 ·Status: TERMINATED ·Phase: NA
-
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
NCT00301834 ·Status: COMPLETED ·Phase: PHASE2
-
Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens
NCT01572181 ·Status: COMPLETED ·Phase: PHASE2
-
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
NCT02793544 ·Status: COMPLETED ·Phase: PHASE2
-
Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission
NCT00305708 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Feasibility Study of Low Level Light Therapy for Prevention of Oropharyngeal Mucositis in Pediatric Transplants Patients
NCT02119897 ·Status: COMPLETED ·Phase: NA
-
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia
NCT01824693 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders
NCT00005893 ·Status: COMPLETED ·Phase: NA
-
Monoclonal Antibody Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia in Remission or First Relapse
NCT00002554 ·Status: COMPLETED ·Phase: PHASE2
-
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
NCT02342613 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies
NCT02354417 ·Status: TERMINATED ·Phase: PHASE1
-
Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation
NCT00004255 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT
NCT01779882 ·Status: COMPLETED ·Phase: NA
-
Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies
NCT01622556 ·Status: TERMINATED ·Phase: PHASE2
-
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
NCT01342289 ·Status: COMPLETED ·Phase: PHASE1
-
Stem Cell Transplant for Bone Marrow Failure Syndromes
NCT00176878 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies
NCT00208923 ·Status: COMPLETED ·Phase: PHASE2